Targeting Residual Risk Beyond SGLT2s & GLP-1s to Discover the Mechanisms Driving Continued CKD Progression
12:00 pm - Thursday 18th March 2027
- Profiling molecular pathways that remain active after current standard-of-care treatment
- Identifying immune, inflammatory and fibrotic mechanisms contributing to persistent progression
- Translating residual disease biology into differentiated therapeutic hypotheses